All articles tagged with #novo holdings
Originally Published 1 year ago — by Financial Times
Novo Holdings' investment ambitions are bolstered by the success of diabetes drugs Ozempic and Wegovy, which have generated significant income. This success is expected to fuel the company's investment activities in various sectors.
Originally Published 1 year ago — by STAT
Novo Holdings, the investment arm of Novo Nordisk’s parent foundation, is acquiring drug manufacturer Catalent for $16.5 billion, a move that will provide Novo with additional sites to expand production of its obesity and diabetes drugs, including the popular treatment Wegovy. As part of the deal, Novo Nordisk is purchasing three of Catalent’s fill-finish sites for $11 billion, which are already involved in the production of Novo’s drugs.
Originally Published 1 year ago — by Endpoints News
Novo Holdings, the investment arm of Novo Nordisk’s parent foundation, is acquiring contract manufacturer Catalent for $16.5 billion in an all-cash deal. Catalent, a major player in the contract development and manufacturing world, is heavily involved in producing Novo Nordisk’s top-selling obesity drug Wegovy. As part of the deal, Novo Holdings will sell three Catalent fill-finish sites and related assets to Novo Nordisk, including ones in Italy, Belgium, and Bloomington, IN.
Originally Published 2 years ago — by Reuters
Novo Holdings, the controlling shareholder of Novo Nordisk, is preparing for a significant windfall from the success of weight-loss drug Wegovy. The Novo Nordisk Foundation, whose wealth and assets are managed by Novo Holdings, could become a major philanthropist and environmental, social, and governance (ESG) investor. Estimates suggest that Wegovy and other drugs will generate returns of over $12 billion in the coming years. Novo Holdings holds a significant stake in Novo Nordisk and expects a substantial increase in its wealth. The foundation plans to use the funds for investments and charitable grants, potentially making it highly influential. Novo Holdings intends to expand its operations, hire more employees, and increase its deal size in healthcare investments. Additionally, the foundation is considering a €200 million investment in a vaccines and immunity initiative.